Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19152014 | 0.87 | MEN1 (0.38) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL22580722 | 0.87 | MEN1 (0.40) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL20967554 | 0.85 | MEN1 (0.34) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL21120326 | 0.85 | MEN1 (0.34) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL22435826 | 0.85 | KDM4E (0.37) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL19752428 | 0.84 | KDM4E (0.36) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL13645518 | 0.82 | KDM4E (0.32) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL24796724 | 0.81 | MEN1 (0.39) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL22882196 | 0.81 | MLNR (0.34) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL21868089 | 0.78 | PDK2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220093873-A1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEM, LTD. (KR) | 2022-03-24 | — | — | US | disclosed |
| US-10745362-B2 | Heterocyclic compound and organic light emitting device comprising same | LG CHEM, LTD. (KR) | 2020-08-18 | — | — | US | disclosed |
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| US-20180127385-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG CHEM LTD. (KR) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | ARF1, ARF5, ARFGAP1 | MEN1 755/4885KMT2A 1622/4885LMNA 4627/4885 |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | ARF1, ARF5, ARFGAP1 | MEN1 755/4885KMT2A 1622/4885LMNA 4627/4885 |
| US-10745362-B2 | Heterocyclic compound and organic light emitting device comprising same | CRY1, CRY2, PER2 | MEN1 847/4885KMT2A 714/4885LMNA 3362/4885 |
| US-20180127385-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | CRY1, CRY2, PER2 | MEN1 847/4885KMT2A 714/4885LMNA 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.